KIR3DL1 and neoplasm: When we further assessed the potential interactions between these two inhibitory KIRs simultaneously, we found that patients who inherited both KIRs in the presence of their ligands (Group 2: KIR2DL2+/HLA-C1+ and KIR3DL1+/HLA-Bw4+) had greater clinical benefit (significant for OR and tumor shrinkage and a trend for PFS) as compared to the complementary group of patients (Group 1: not KIR2DL2+/HLA-C1+ and KIR3DL1+/HLA-Bw4+) (Fig. 4).